Make Informed Investment Decisions with Affordable Access to Experts
Understanding the standard of care, current treatment paradigm and the unmet need in treating squamous cell carcinoma of the head and neck (HNSCC) with a focus on IOVA's LN-145Ticker(s): IOVA
Name: Dr Paul Swiecicki - MD
Institution: University of Michigan
- Medical Oncologist specializing in cancer of the head and neck and Clinical Assistant Professor, Internal Medicine - Hematology/Oncology at the University of Michigan.
- Clinical and research focus is exclusively HNSCC; sees approximately 14-17 new patients per month with HNSCC and active patient panel (on treatment) of 100 patients.
- Member of the NCI Task force for Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma that recently reviewed the tipifarnib data, and involved in numerous clinical trials.
Please describe your clinical practice; roughly how many patients with HNSCC do you currently manage?
What is your current first line therapy in treating HNSCC?Added By: c_admin
What are your thoughts on the potential for TIL therapies in this disease?Added By: c_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.